Core Insights - American Oncology Network (AON) is participating in 14 speaking sessions at the 2025 Community Oncology Alliance (COA) Annual Conference, focusing on advocacy, innovation, and access in independent community oncology [1][2] Group 1: Conference Details - The conference will take place on April 29-30, 2025, in Orlando, Florida, under the theme "Empower & Advocate: Independent Community Oncology" [1] - AON leaders will discuss various topics including payer contracting, value-based care, patient advocacy, clinical trials, and mental health programs [2][4] Group 2: Leadership and Contributions - Stephen "Fred" Divers, MD, AON's chief medical officer, emphasizes the importance of local practices in delivering patient-centered care [2] - Alti Rahman, AON chief strategy and innovation officer, highlights the shared mission of AON and COA to protect and promote independent oncology [5] Group 3: AON's Support Services - AON provides comprehensive support services to independent oncology practices, including in-house pharmacy, lab services, and revenue-diversifying programs [5][7] - The organization aims to enable physicians to focus on high-quality care without reliance on hospital systems or third-party providers [5][7] Group 4: Commitment to Health Equity - AON is dedicated to promoting health equity by addressing disparities in cancer care and ensuring access to quality care for all patients [7]

Strategic Thyme Care partnership strengthens AON's leadership in value-based care innovation while improving patient experience and reducing costs FORT MYERS, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced strong results from the first performance period in the Centers for Medicare & Medicaid Innovation's (CMMI) Enhancing Oncology Model (EOM). AON practices participating in the program—in collaboratio ...

Financial Data and Key Metrics Changes - For the full year 2024, the company recognized approximately EUR2.8 billion in revenues, a decrease from around EUR3.8 billion in 2023, primarily due to lower COVID-19 vaccine market demand [57][58] - The net loss for 2024 was EUR665 million, compared to a net profit of EUR930 million in the prior year [61] - The diluted loss per share for 2024 was EUR2.77, compared to EUR3.83 for the prior year [61] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses for 2024 reached approximately EUR2.3 billion, up from roughly EUR1.8 billion in 2023, driven by advancing priority programs [58] - Selling, general and administrative (SG&A) expenses for 2024 amounted to approximately EUR599 million, compared to EUR558 million in 2023, primarily due to the build-out of the commercial organization [59] Market Data and Key Metrics Changes - The company maintained a leading market share globally for its COVID-19 vaccine in collaboration with Pfizer [15] - The revenue guidance for 2025 is projected to be in the range of EUR1.7 billion to EUR2.2 billion, assuming stable vaccination rates and market share compared to 2024 [65] Company Strategy and Development Direction - The company aims to become a fully integrated biopharmaceutical company with multiple approved products, focusing on oncology and infectious diseases [8][10] - Significant investments are being made in clinical development for key programs, including BNT327 and mRNA cancer immunotherapies, with a strategic focus on late-stage trials [11][67] - The acquisition of Biotheus is expected to enhance the company's capabilities in immunotherapy and expand its global development efforts [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the company's intellectual property and its ability to navigate ongoing legal disputes [80] - The company anticipates 2025 to be a data-rich year with multiple updates across its oncology pipeline, particularly for BNT327 and mRNA cancer immunotherapies [72][74] Other Important Information - The company plans to share multiple clinical updates throughout 2025, including data for BNT327 and its mRNA cancer immunotherapies at upcoming oncology conferences [74] - The company expects to continue its commercial build-out for oncology in preparation for potential product launches [69] Q&A Session Summary Question: Overview of legal events and potential outcomes - Management indicated that predicting the timing of legal disputes is challenging and referred to the 20-F filing for detailed explanations [79] Question: Context for FixVac data in melanoma - Management confirmed that the FixVac candidate BNT111 met its primary endpoint in a Phase 2 trial and further data will be presented later this year [82] Question: Status of partnership for BNT327 - Management stated that they are currently proceeding independently with BNT327 but are evaluating potential collaborations for broader applications [92] Question: Efficacy expectations for BNT323 in endometrial cancer - Management expects response rates around 50% for HER2+ tumors and is confident in meeting registration requirements [112] Question: Expectations for upcoming data on small cell lung cancer - Management anticipates further validation of previous data with new datasets expected to support aggressive movement into pivotal trials [119]

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 18, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) 85-3009869 (I ...